Thymosin Alpha-1: the complete guide
Thymosin Alpha-1 is a natural immunomodulatory peptide originally isolated from the thymus. It is studied for its effects on T-cell function, chronic viral infection, and post-illness immune recovery.
How Thymosin Alpha-1 works
Tα1 activates toll-like receptor 9, stimulates T-cell differentiation and maturation, and enhances innate and adaptive immune responses.
Typical Thymosin Alpha-1 dosage
Commonly reported research ranges: 1.6 mg subcutaneous, 2x weekly (typical protocols).
Dose should always be individualized. Factors that influence it include bodyweight, research goal, tolerance, and specific compound batch. The information below is educational, not a prescription.
How to reconstitute Thymosin Alpha-1
A widely used reconstitution for a 10 mg vial is 2 ml of bacteriostatic water. With a typical 1600 mcg dose this works out to the unit count shown in the calculator below.
Half-life and administration frequency
Approximately 2 hours.
This half-life informs how often Thymosin Alpha-1 is typically dosed. Shorter half-lives usually mean more frequent dosing to maintain plasma levels; longer half-lives allow daily, weekly, or less-frequent administration depending on the compound.
Reported side effects
- Injection-site reactions
- Rare flu-like symptoms early in treatment
- Generally well tolerated
This list reflects effects reported in available literature or user logs. It is not exhaustive. Adverse reactions should be discussed with a qualified clinician.
Common Thymosin Alpha-1 stacks
- Used alone; occasionally with thymosin beta-4 in research
Full editorial stack guides featuring Thymosin Alpha-1:
Storage and handling
Lyophilized refrigerated. Reconstituted: refrigerated, use within 28 days.
FDA and regulatory status
Approved in ~35 countries for hepatitis B/C; not FDA approved in the US (Zadaxin). Widely used compounded in research settings.
Thymosin Alpha-1 clinical trials and evidence
For clinical-trial and primary-literature context, start with the sources below. We prioritize official drug labels, ClinicalTrials.gov records, and PubMed-indexed literature when available.
- Thymosin alpha-1 clinical trial records — ClinicalTrials.gov
Track your Thymosin Alpha-1 protocol on iPhone
Peptide Protocol logs every dose, calculates reconstitution for you, and keeps your full protocol on one calm screen.
See the app →Frequently asked questions
What is Thymosin Alpha-1?
Thymosin Alpha-1 is a natural immunomodulatory peptide originally isolated from the thymus. It is studied for its effects on T-cell function, chronic viral infection, and post-illness immune recovery.
How does Thymosin Alpha-1 work?
Tα1 activates toll-like receptor 9, stimulates T-cell differentiation and maturation, and enhances innate and adaptive immune responses.
What is a typical Thymosin Alpha-1 dose?
Commonly reported ranges are 1.6 mg subcutaneous, 2x weekly (typical protocols). This is research information, not a recommendation — dosing should be individualized under clinical guidance.
What is the half-life of Thymosin Alpha-1?
Approximately 2 hours. This influences how often it is administered.
How do you reconstitute Thymosin Alpha-1?
A common approach is to add 2 ml of bacteriostatic water to a 10 mg vial. Use the reconstitution calculator for exact unit counts.
What are the side effects of Thymosin Alpha-1?
Injection-site reactions; Rare flu-like symptoms early in treatment; Generally well tolerated.
Is Thymosin Alpha-1 FDA approved?
Approved in ~35 countries for hepatitis B/C; not FDA approved in the US (Zadaxin). Widely used compounded in research settings.
Are there clinical trials for Thymosin Alpha-1?
Registered or published clinical-trial sources for Thymosin Alpha-1 are listed in the references section below. Evidence depth varies widely by compound, so check the cited trial registries and primary literature before relying on any claim.
References
- Thymosin alpha-1 literature (PubMed) — National Library of Medicine. Primary research on thymalfasin immune-modulation activity
- Zadaxin (thymalfasin) regulatory context — EMA and international approvals — PubMed. Approved outside US for hepatitis B/C adjunct use; not FDA approved
- Thymosin alpha-1 clinical trial records — ClinicalTrials.gov. Registered human studies across hepatitis, sepsis, oncology
Sources listed above were used to verify the claims on this page. See our editorial policy for how we source information.
Educational use only. Peptide Protocol is an informational tool. Nothing on this page constitutes medical advice. Many peptides are prescription-only or restricted in your jurisdiction. Always consult a licensed healthcare professional before injecting any compound.